Nname change resolutions approved at an Extraordinary General Meeting (“EGM”) held on December 4, 2018, have been approved by the ‘Bolagsverket’ in Sweden.
|
LUND, Sweden, Dec. 20, 2018 /PRNewswire/ -- Hansa Medical AB (publ) (Nasdaq Stockholm:HMED) ("Hansa Medical" or the "Company"), the leading biopharma company focusing on inhibition of immunoglobulin G (IgG)-mediated immunopathologies, today announced that the name change resolutions approved at an Extraordinary General Meeting ("EGM") held on December 4, 2018, have been approved by the 'Bolagsverket' in Sweden. The name change will be implemented in the next days and weeks and the Company stock ticker symbol has changed from "HMED" to "HNSA". The information was submitted for publication, through the agency of the contact person set out below, at 2:15 pm CET on December 20, 2018. CONTACT: For further information, please contact: Company:
Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Medical AB (publ)
Mobile: +46-707-175477 E-mail: emanuel.bjorne@hansamedical.com Swedish Investor and Media Relations:
Cord Communications
Mikael Widell +46-70-311-99-60 U.K. Investor and Media Relations
FTI Consulting
Simon Conway/ Stephanie Cuthbert +44 (0)20 3727 1000 U.S. Investor and Media Relations:
Argot Partners
Stephanie Marks/ David Rosen (media) +1-212-600-1902 This information was brought to you by Cision http://news.cision.com The following files are available for download:
SOURCE Hansa Medical |
||
Company Codes: Bloomberg:HNSA@SS, ISIN:SE0002148817, RICS:HNSA.ST, Stockholm:HNSA |
View original content:
